Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. (2020)
Attributed to:
Joint Wellcome and MRC Centre, ‘Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute’
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1182/blood.2020005037
PubMed Identifier: 32589720
Publication URI: http://europepmc.org/abstract/MED/32589720
Type: Journal Article/Review
Volume: 136
Parent Publication: Blood
Issue: 21
ISSN: 0006-4971